MDSC (myeloid-derived suppressor cells) are a heterogenous group of immune cells from the myeloid lineage (a family of cells that originate from bone marrow stem cells). MDSCs strongly expand in pathological situations such as chronic infections and cancer, as a result of an altered haematopoiesis (def.: process of blood cell formation.)
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
abstract:
Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer
Highlights
- •Low MDSC in peripheral blood correlate with response to chemo-immunotherapy.
- •Increased antigen specific T cells recognizing IGF-1R correlate with responses.
- •There was no advantage in overall survival with this combination compared to nab-paclitaxel alone.
Background
Granulocyte
macrophage colony-stimulating factor (GM-CSF) stimulates immunity via
recruitment of antigen presenting cells and tumor specific T-cell
stimulation. Albumin-bound paclitaxel (nab-paclitaxel) followed by
GM-CSF may enhance antitumor responses and prolong remissions in ovarian
cancer. Immune phenotypes present before treatment may identify
responders to chemo-immunotherapy.
Methods
Recurrent platinum-resistant ovarian, peritoneal, or fallopian tube cancer patients received nab-paclitaxel, 100 mg/m2
days 1, 8, 15 followed by GM-CSF 250 μg days 16–26 every 28 days for 6
planned cycles. The primary endpoint was remission duration compared to
immediate prior remission. Peripheral blood was evaluated by flow
cytometry and interferon-γ ELISPOT.
Results
Twenty-one
patients were enrolled. Six patients (29%) achieved a biochemical
complete response and 9 (43%) a partial response for an overall response
rate of 72%. Median time to progression was 4 months and 10% of
patients achieved longer remissions than the immediate prior regimen.
Median overall survival (OS) was 16.8 months. Fewer myeloid derived
suppressor cells (MDSC) at enrollment significantly associated with
complete response (p = 0.05). T-cell responses to IGF1R-p1332–1346
(r = 0.827, p = 0.0003) and IGF1R-p1242–1256 (r = 0.850, p = 0.0001)
during treatment correlated with time to progression.
Conclusions
Nab-paclitaxel
combined with GM-CSF demonstrated biochemical responses in a majority
of patients, although responses were not sustained. This combination did
not demonstrate an advantage in OS over prior studies of nab-paclitaxel
monotherapy. Agents that modulate MDSC should be studied as potential
adjuvants to therapy. Strategies to expand T cells recognizing
tumor-associated antigens biologically significant in ovarian cancer
should also continue to be investigated.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.